Fenwick represented Mythic Therapeutics, a product-platform company developing a pipeline of antibody-drug conjugates, in its $103 million Series B financing.
The round was led by Viking Global Investors and included participation from new investors such as Venrock Healthcare Capital Partners, Foresite Capital, Perceptive Advisors and Highside Capital. Existing Mythic investors participating in the round included First Round Capital, OMX Ventures, Lifeforce Capital and Refactor Capital.
Mythic Therapeutics will use the proceeds from the round to finance the lead program through first-in-human clinical studies in lung cancer and fund pipeline development. More information can be obtained from the company’s announcement.
The Fenwick transaction team was led by corporate partners Effie Toshav and Josh Geffon and included associates Caroline Wells, Andrew Webber and Elizabeth Gil and technology transactions associate Kehl Sink.